Nexity (0KB3)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 4.347 |
|---|---|
| 52-week range | 4.347 – 10.240 |
| Return, 1 month / 3 months | −16.0% / −40.2% |
| Return, 1 year / 3 years | −57.3% / −66.3% |
| Trend | Below its 200-day average |
| RSI (14) | 30 |
| Volatility (1 year) | 42.5% |
| Worst drawdown (1 year) | -56.4% |
| Average daily value traded | 0.01M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Nexity is a French real estate group based in Paris. It develops residential housing and sells new homes to individual buyers, and it also runs a services business covering property management, rental management and real estate transactions for homeowners, investors and local authorities. Its operations span development, services and distribution of property across France, with activities in urban development and commercial real estate as well as housing.
On this site Nexity appears as a stock on the London Exchange (UK), code 0KB3, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Nexity (0KB3) trades on the London Exchange in UK. It last closed at EUR 4.347 on 23 October 2026.
Its price-based Market X-Ray is 12 out of 100 (a weak price profile), ranking 3,661 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 57.3% and over the last three months it fell 40.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 6 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -42.6% | ||
| From 52-week high | -57.3% | ||
| Momentum | 4 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -40.2% | ||
| 6-month return | -50.2% | ||
| 12-month return, skipping the last month | -49.1% | ||
| Stability (higher is calmer) | 26 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 42.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -56.4% | ||
| Liquidity | 11 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M EUR | ||
| Zero-volume days | 10.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −8.7% |
|---|---|
| 1 month | −16.0% |
| 3 months | −40.2% |
| 6 months | −50.2% |
| 1 year | −57.3% |
| 3 years | −66.3% |
| 5 years | −86.4% |
Signals
| 50-day / 200-day average | 5.598 / 7.577 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.593 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 May 2023 | EUR 2.5000 |
| 23 May 2022 | EUR 2.5000 |
| 25 May 2021 | EUR 2.0000 |
| 25 May 2020 | EUR 2.0000 |
| 27 May 2019 | EUR 2.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.